Patient baseline characteristics
| Characteristic . | Salvage cohort (n = 54) . | Bridging cohort (n = 51) . | P . |
|---|---|---|---|
| Median age, y (range) | 73.5 (37-87) | 61 (22-82) | <.001 |
| Male (%) | 37 (68.5) | 39 (76.5) | .4 |
| Diagnosis (%) | |||
| DLBCL | 49 (90.7) | 48 (94.1) | .7 (DLBCL vs other) |
| GCB | 16 (29.6) | 19 (37.3) | |
| ABC | 13 (24.1) | 7 (13.7) | |
| COO unknown | 20 (37.0) | 22 (43.1) | |
| PMBCL | 0 | 1 (2) | |
| HGBCL | 5 (9.3) | 2 (3.9) | |
| NOS | 3 (5.6) | 0 | |
| With MYC and BCL2 and/or BCL6 rearrangements | 2 (3.7) | 2 (3.9) | |
| Proportion of transformed lymphoma (%) | 15 (27.8) | 9 (17.6) | .3 |
| Time from diagnosis, mo (range) | 18.6 (4.6-143) | 13.4 (2.4-120) | .096 |
| Prior systemic treatment lines (range) | 3 (2-8) | 3 (2-6) | .49 |
| Failed autoHCT (%) | 5 (9.3) | 16 (31.4) | .007 |
| Failed alloHCT (%) | 2 (3.7) | 5 (9.8) | .3 |
| Failed CAR T-cell therapy (%) | 5 (9.3) | 7 (13.7) | .5 |
| Refractoriness to last pretreatment (%) | 47 (87) | 43 (84.3) | .8 |
| Characteristic . | Salvage cohort (n = 54) . | Bridging cohort (n = 51) . | P . |
|---|---|---|---|
| Median age, y (range) | 73.5 (37-87) | 61 (22-82) | <.001 |
| Male (%) | 37 (68.5) | 39 (76.5) | .4 |
| Diagnosis (%) | |||
| DLBCL | 49 (90.7) | 48 (94.1) | .7 (DLBCL vs other) |
| GCB | 16 (29.6) | 19 (37.3) | |
| ABC | 13 (24.1) | 7 (13.7) | |
| COO unknown | 20 (37.0) | 22 (43.1) | |
| PMBCL | 0 | 1 (2) | |
| HGBCL | 5 (9.3) | 2 (3.9) | |
| NOS | 3 (5.6) | 0 | |
| With MYC and BCL2 and/or BCL6 rearrangements | 2 (3.7) | 2 (3.9) | |
| Proportion of transformed lymphoma (%) | 15 (27.8) | 9 (17.6) | .3 |
| Time from diagnosis, mo (range) | 18.6 (4.6-143) | 13.4 (2.4-120) | .096 |
| Prior systemic treatment lines (range) | 3 (2-8) | 3 (2-6) | .49 |
| Failed autoHCT (%) | 5 (9.3) | 16 (31.4) | .007 |
| Failed alloHCT (%) | 2 (3.7) | 5 (9.8) | .3 |
| Failed CAR T-cell therapy (%) | 5 (9.3) | 7 (13.7) | .5 |
| Refractoriness to last pretreatment (%) | 47 (87) | 43 (84.3) | .8 |
Salvage chemoimmunotherapy followed by high-dose chemotherapy and autologous hematopoietic cell transplantation was counted as 1 treatment line. Refractoriness to last pretreatment was defined as no response or progression within 6 mo of last treatment.
ABC, activated B cell; COO, cell of origin; GCB, germinal-center B cell; PMBCL, primary mediastinal B-cell lymphoma.